Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) has confirmed that the first patient in its phase 1 CEP-2 trial has been enrolled and dosed at the prestigious City of Hope Cancer Center, California.
Patient recruitment is ongoing, and the company expects to open further US trial sites in due course.
The first safety results will be reported once patient cohort 1 has completed the first cycle of combination therapy. The City of Hope Cancer Center is an influential medical institution and is considered one of the most world-renowned cancer hospitals in the USA according to the US News & World Report.
It is consistently ranked as a top cancer treatment centre in the US and is also a founding member of the National Comprehensive Cancer Network, a non-profit alliance of 21 US cancer centres that publishes clinical practice guidelines for cancer treatment.
We are delighted to have dosed the first patient in the CEP-2 trial. The study investigates the use of Veyonda in combination with the chemotherapy drug doxorubicin for the treatment of approximately 30 patients with soft tissue sarcoma, which is an aggressive cancer in urgent need of new treatment options,” Dr Mark Agulnik, CEP-2 Principal Investigator at the City of Hope Cancer Center, said.
The CEP-2 study builds on the findings from CEP-1, as published in the peer-reviewed journal Current Therapeutic Research.
Noxopharm CEO, Dr Gisela Mautner, said the Australian biotech company has managed to attract the depth of talent and experience needed to work with prestigious US institutions such as City of Hope for the CEP-2 study, along with MD Anderson Cancer Center and Beverly Hills Cancer Center for our DARRT programme
“We look forward to adding additional world-renowned study sites in the near future.”
About the CEP-2 Trial
CEP-2 is a Phase 1, open-label, dose-escalation and dose-expansion study of Veyonda administered to cohorts of patients being treated with doxorubicin for the treatment of metastatic soft tissue sarcoma.
Approximately 30 patients in the United States with a range of soft tissue sarcomas are being enrolled to be treated with the Veyonda / doxorubicin combination as a first-line treatment.
A number of major sites are participating in CEP-2, the first, the City of Hope Cancer Center in Los Angeles has commenced treatment, with other sites to be activated shortly.
The CEP-Programme is based on pre-clinical and clinical findings of Veyonda enhancing the anti-cancer effect of a number of standard chemotherapeutic agents.
